View clinical trials related to E-cigarette Use.
Filter by:The purpose of this study is to examine the effect of exposure to vape education messages on beliefs, perceptions, norms, and behaviors related to electronic vapor product use.
To date the majority of experimental tobacco regulatory science has focused specifically on the impact of possible tobacco product standards (e.g. limiting e-cigarette flavor) on the use of the single tobacco product targeted by the standard (e.g. e-cigarettes) among individuals who primarily or solely use the targeted product (e.g. vapers). Whereas this "single target" approach has yielded a large amount of actionable evidence, it has also resulted in a significant gap in the regulatory science evidence base for two reasons: First, the focus on single tobacco product users has resulted in very little evidence regarding the impact of possible new product standards among multiple tobacco product (MTP) users. MTP users make up a sizeable proportion (30-40%) of the tobacco using population and individuals who use e-cigarettes (EC) and combusted cigarettes (CC) comprise the largest MTP using group (40% of MTP users). A lack of data on this population means that estimates of the impact of new product standards on public health are incomplete. Despite some data derived from hypothetical tasks, little experimental research exists to evaluate how potential tobacco regulations might impact the use of other tobacco products in addition to the targeted product. It is critical to anticipate how potential restrictions on the EC market may impact EC and other tobacco product-such as CC-use. In the proposed research, we will recruit young adult (age 21-29) dual EC/CC users evaluate the demand for participants' usual brand CC as compared to EC that vary in nicotine content (e.g., 5% vs. 3% pods). Participants will engage in a validated concurrent choice task in which they will work for fixed doses of EC vapor or CC smoke in exchange for expended effort. In addition, we will seek to answer this question in samples of dual EC and CC users-individuals who, because they regularly use both EC and CC, are most vulnerable to changes in the appeal of EC and CC brought about by a product standard limiting EC flavors.
This is a human randomized controlled cross-over study where the effects of e-cigarette inhalation (with or without nicotine) on vascular function, microcirculation and thrombosis is assessed.
This study is designed to enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes ("products") to well-validated cardiovascular and pulmonary disease biomarkers. Participants will be enrolled in 3 groups: exclusive e-cigarette users, exclusive cigarette smokers, and a control group of never-users. Participants can expect up to 4 weeks of study participation.
The investigators aim to (1) establish a methodology for the evaluation of the biodistribution of radio-labeled nicotine following e-cigarette use, (2) determine the oral/pulmonary distribution of nicotine following e-cigarette use, and (3) determine the lowest required dose using the new digital PET/CT technology to provide detailed or accurate oral/pulmonary distribution data following e-cigarette use. Potential participants will be identified using advertisements such as brochures and online social media postings. After participants are identified, their eligibility will be determined using survey tools. All eligible participants will first have a screening visit at the WCIBMI for study participation. During this initial visit, subjects will be informed about the study in detail, and the relevant consent form will be reviewed and signed. If the participant agrees to participate, they will go through a full dress rehearsal. Up to 10 volunteers will only participate in the dress rehearsal. All other volunteers (30) will have a dress rehearsal without radiation exposure on day 1, and then on a second day, they will participate in the full imaging study using 11C-nicotine. During the imaging study, S-nicotine will be labeled with 11C and placed in the cartridge of an e-cigarette. There will be two dose groups: (A) 3 mCi dosage or (B) 9 mCi doses. The investigators intend to use dose level A; however, if it does not lead to the expected results, an alternate dose level as an option is needed, which is the 9 mCi (B) dose level. Subjects will take a maximum of 10 puffs (1 puff per 30 seconds) from the e-cigarette while positioned in the PET/CT system. Dynamic PET/CT imaging will be performed for a maximum of 60 minutes following inhalation. The subject will be placed in the PET camera in order to generate axial images of the following regions: head/neck (e.g., brain, oral cavity, and throat) and thorax (e.g., trachea, lungs). From the PET/CT images, quantitative radioactivity deposition will be determined, and the biodistribution and uptake/clearance will be evaluated. PET data will be acquired in listmode and subsequently used for simulation to determine the potentially lowest dose feasible using the next generation digital PET/CT technology.